liu.seSearch for publications in DiVA
Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • harvard1
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • oxford
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
RNA aptamer-based functional ligands of the neurotrophin receptor, TrkB
Department of Neurobiology, Duke University of Medical Center, Duke University, Durham, NC, United States.
Department of Internal Medicine, University of of Iowa, MERF, 375 Newton Rd., Iowa City, IA 52242, United States.
Department of Pharmacology and Cancer Biology, Duke University of Medical Center, Duke University, Durham, NC, United States.
Department of Internal Medicine, University of of Iowa, MERF, 375 Newton Rd., Iowa City, IA 52242, United States.
Show others and affiliations
2012 (English)In: Molecular Pharmacology, ISSN 0026-895X, E-ISSN 1521-0111, Vol. 82, no 4, 623-635 p.Article in journal (Refereed) Published
Abstract [en]

Many cell surface signaling receptors, such as the neurotrophin receptor, TrkB, have emerged as potential therapeutic targets for diverse diseases. Reduced activation of TrkB in particular is thought to contribute to neurodegenerative diseases. Unfortunately, development of therapeutic reagents that selectively activate particular cell surface receptors such as TrkB has proven challenging. Like many cell surface signaling receptors, TrkB is internalized upon activation; in this proof-of-concept study, we exploited this fact to isolate a pool of nuclease-stabilized RNA aptamers enriched for TrkB agonists. One of the selected aptamers, C4-3, was characterized with recombinant protein-binding assays, cell-based signaling and functional assays, and, in vivo in a seizure model in mice. C4-3 binds the extracellular domain of TrkB with high affinity (KD ∼2 nM) and exhibits potent TrkB partial agonistic activity and neuroprotective effects in cultured cortical neurons. In mice, C4-3 activates TrkB upon infusion into the hippocampus; systemic administration of C4-3 potentiates kainic acid-induced seizure development. We conclude that C4-3 is a potentially useful therapeutic agent for neurodegenerative diseases in which reduced TrkB activation has been implicated. We anticipate that the cell-based aptamer selection approach used here will be broadly applicable to the identification of aptamer-based agonists for a variety of cell-surface signaling receptors. Copyright © 2012 The American Society for Pharmacology and Experimental Therapeutics.

Place, publisher, year, edition, pages
Bethesda, United States: American Society for Pharmacology and Experimental Therapeutics , 2012. Vol. 82, no 4, 623-635 p.
National Category
Cell and Molecular Biology
Identifiers
URN: urn:nbn:se:liu:diva-143337DOI: 10.1124/mol.112.078220ISI: 000309509900008PubMedID: 22752556Scopus ID: 2-s2.0-84866849562OAI: oai:DiVA.org:liu-143337DiVA: diva2:1162520
Available from: 2017-12-04 Created: 2017-12-04 Last updated: 2017-12-13Bibliographically approved

Open Access in DiVA

No full text

Other links

Publisher's full textPubMedScopus

Authority records BETA

Hernandez, Frank J

Search in DiVA

By author/editor
Hernandez, Frank J
In the same journal
Molecular Pharmacology
Cell and Molecular Biology

Search outside of DiVA

GoogleGoogle Scholar

doi
pubmed
urn-nbn

Altmetric score

doi
pubmed
urn-nbn
Total: 53 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • harvard1
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • oxford
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf